Maxwell Skor
Stock Analyst at Morgan Stanley
(4.75)
# 456
Out of 4,698 analysts
237
Total ratings
70.1%
Success rate
24.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Downgraded: Hold | $74 → $18 | $15.30 | +17.65% | 14 | Sep 3, 2026 | |
| ASND Ascendis Pharma | Rated: Buy | $275 → $273 | $270.56 | +0.90% | 28 | Sep 1, 2026 | |
| PHVS Pharvaris | Rated: Buy | $46 | $35.25 | +30.50% | 90 | Aug 31, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintained: Hold | $60 | $55.79 | +7.55% | 3 | Aug 28, 2026 | |
| INSM Insmed | Maintained: Buy | $218 | $126.29 | +72.62% | 27 | Aug 24, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Hold | n/a | $4.30 | - | 9 | Aug 17, 2026 | |
| MNPR Monopar Therapeutics | Rated: Buy | $115 → $130 | $117.56 | +10.58% | 4 | Aug 17, 2026 | |
| SANA Sana Biotechnology | Rated: Buy | $12 | $3.85 | +211.69% | 4 | Aug 17, 2026 | |
| ADAG Adagene | Maintained: Hold | n/a | $3.58 | - | 7 | Aug 17, 2026 | |
| TCRX TScan Therapeutics | Maintained: Hold | n/a | $0.3915 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $8.49 | +53.12% | 1 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $7 | $5.83 | +20.07% | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $103 | $72.72 | +41.64% | 21 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9.5 → $3.55 | $0.826 | n/a | 10 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.25 | $0.759 | n/a | 1 | Sep 25, 2023 |
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $74 → $18
Current: $15.30
Upside: +17.65%
Ascendis Pharma
Sep 1, 2026
Rated: Buy
Price Target: $275 → $273
Current: $270.56
Upside: +0.90%
Pharvaris
Aug 31, 2026
Rated: Buy
Price Target: $46
Current: $35.25
Upside: +30.50%
CRISPR Therapeutics AG
Aug 28, 2026
Maintained: Hold
Price Target: $60
Current: $55.79
Upside: +7.55%
Insmed
Aug 24, 2026
Maintained: Buy
Price Target: $218
Current: $126.29
Upside: +72.62%
Bicycle Therapeutics
Aug 17, 2026
Maintained: Hold
Price Target: n/a
Current: $4.30
Upside: -
Monopar Therapeutics
Aug 17, 2026
Rated: Buy
Price Target: $115 → $130
Current: $117.56
Upside: +10.58%
Sana Biotechnology
Aug 17, 2026
Rated: Buy
Price Target: $12
Current: $3.85
Upside: +211.69%
Adagene
Aug 17, 2026
Maintained: Hold
Price Target: n/a
Current: $3.58
Upside: -
TScan Therapeutics
Aug 17, 2026
Maintained: Hold
Price Target: n/a
Current: $0.3915
Upside: -
Aug 13, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $8.49
Upside: +53.12%
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $5.83
Upside: +20.07%
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $72.72
Upside: +41.64%
Nov 20, 2024
Maintained: Buy
Price Target: $9.5 → $3.55
Current: $0.826
Upside: n/a
Sep 25, 2023
Downgraded: Hold
Price Target: $3.25
Current: $0.759
Upside: n/a